Robert J Klaassen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5704278/publications.pdf

Version: 2024-02-01

154 papers 3,453 citations

147801 31 h-index 53 g-index

157 all docs

157 docs citations

157 times ranked

4227 citing authors

#	Article	IF	CITATIONS
1	"Low-Risk―Prediction Rule for Pediatric Oncology Patients Presenting With Fever and Neutropenia. Journal of Clinical Oncology, 2000, 18, 1012-1012.	1.6	207
2	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 2013, 121, 2596-2606.	1.4	179
3	Impact of Caring for a Child With Cancer on Parents' Health-Related Quality of Life. Journal of Clinical Oncology, 2008, 26, 5884-5889.	1.6	177
4	Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood, 2014, 124, 2867-2871.	1.4	162
5	Identifying determinants of quality of life of children with cancer and childhood cancer survivors: a systematic review. Supportive Care in Cancer, 2011, 19, 1275-1287.	2.2	105
6	A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood, 2013, 122, 112-123.	1.4	101
7	Quality of life during active treatment for pediatric acute lymphoblastic leukemia. International Journal of Cancer, 2011, 128, 1213-1220.	5.1	87
8	Validity, Reliability, and Responsiveness of a New Measure of Health-Related Quality of Life in Children with Immune Thrombocytopenic Purpura: The Kids' ITP Tools. Journal of Pediatrics, 2007, 150, 510-515.e1.	1.8	82
9	Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes. Journal of Medical Genetics, 2015, 52, 575-584.	3.2	78
10	Paediatric health-related quality of life: what is it and why should we measure it?. Archives of Disease in Childhood, 2017, 102, 393-400.	1.9	77
11	Identification of paediatric cancer patients with poor quality of life. British Journal of Cancer, 2009, 100, 82-88.	6.4	75
12	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatric Blood and Cancer, 2016, 63, 1407-1413.	1.5	70
13	Parents of children with cancer: Which factors explain differences in healthâ€related quality of life. International Journal of Cancer, 2011, 129, 1190-1198.	5.1	68
14	Considering quality of life for children with cancer: a systematic review of patient-reported outcome measures and the development of a conceptual model. Quality of Life Research, 2014, 23, 771-789.	3.1	67
15	Randomized Placebo-Controlled Trial of Oral Antibiotics in Pediatric Oncology Patients at Low-Risk With Fever and Neutropenia. The American Journal of Pediatric Hematology/oncology, 2000, 22, 405-411.	1.3	60
16	Genetic analysis of inherited bone marrow failure syndromes from one prospective, comprehensive and population-based cohort and identification of novel mutations. Journal of Medical Genetics, 2011, 48, 618-628.	3.2	55
17	Relationships among bleeding severity, healthâ€related quality of life, and platelet count in children with immune thrombocytopenic purpura. Pediatric Blood and Cancer, 2009, 53, 652-654.	1.5	51
18	Caregiving, single parents and cumulative stresses when caring for a child with cancer. Child: Care, Health and Development, 2014, 40, 184-194.	1.7	51

#	Article	lF	Citations
19	Comparative analysis of Shwachman-Diamond syndrome to other inherited bone marrow failure syndromes and genotype-phenotype correlation. Clinical Genetics, 2011, 79, 448-458.	2.0	50
20	Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica, 2016, 101, 781-788.	3.5	50
21	Clinical and Genetic Analysis of Unclassifiable Inherited Bone Marrow Failure Syndromes. Pediatrics, 2008, 122, e139-e148.	2.1	49
22	Understanding the health impact of caregiving: a qualitative study of immigrant parents and single parents of children with cancer. Quality of Life Research, 2012, 21, 1595-1605.	3.1	48
23	Communication and language challenges experienced by Chinese and South Asian immigrant parents of children with cancer in Canada: Implications for health services delivery. Pediatric Blood and Cancer, 2012, 58, 572-578.	1.5	47
24	Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. British Journal of Cancer, 2016, 114, 623-630.	6.4	47
25	Measuring disease-specific quality of life in rare populations: a practical approach to cross-cultural translation. Health and Quality of Life Outcomes, 2009, 7, 92.	2.4	46
26	Pilot study of the effect of romiplostim on child healthâ€related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatric Blood and Cancer, 2012, 58, 395-398.	1.5	41
27	Rasch analysis of the PedsQL: an increased understanding of the properties of a rating scale. Journal of Clinical Epidemiology, 2012, 65, 1117-1123.	5.0	40
28	Secondâ€ine treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. American Journal of Hematology, 2019, 94, 741-750.	4.1	37
29	Validation and reliability of a diseaseâ€specific quality of life measure (the) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Haematology, 2014, 164, 431-437.	10 Tf 50 3 2.5	47 Td (<scp 36</scp
30	Immigrant to Canada, newcomer to childhood cancer: a qualitative study of challenges faced by immigrant parents. Psycho-Oncology, 2012, 21, 558-562.	2.3	34
31	Quality of life in childhood immune thrombocytopenia: International validation of the kids' ITP tools. Pediatric Blood and Cancer, 2013, 60, 95-100.	1.5	33
32	Health-related Quality of Life: Changes in Children Undergoing Chemotherapy. Journal of Pediatric Hematology/Oncology, 2008, 30, 292-297.	0.6	31
33	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematology,the, 2018, 5, e252-e260.	4.6	31
34	Physician decision making in selection of secondâ€ine treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	4.1	30
35	Evaluating the ability to detect change of healthâ€related quality of life in children with Hodgkin disease. Cancer, 2010, 116, 1608-1614.	4.1	29
36	Exploring predictors of optimism among parents of children with cancer. Psycho-Oncology, 2011, 20, 411-418.	2.3	29

#	Article	IF	Citations
37	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood and Cancer, 2012, 58, 221-225.	1.5	29
38	Nutrient Insufficiencies/Deficiencies in Children With Sickle Cell Disease and Its Association With Increased Disease Severity. Pediatric Blood and Cancer, 2016, 63, 1060-1064.	1.5	29
39	Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood, 2014, 123, 451-452.	1.4	27
40	Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation. Haematologica, 2016, 101, 1508-1515.	3.5	27
41	Initial Bone Marrow Aspiration in Childhood Idiopathic Thrombocytopenia: Decision Analysis. The American Journal of Pediatric Hematology/oncology, 2001, 23, 511-518.	1.3	26
42	Evaluating familyâ€eentred service in paediatric oncology with the measure of processes of care (MPOCâ€20). Child: Care, Health and Development, 2009, 35, 16-22.	1.7	26
43	Familyâ€centred care: a qualitative study of Chinese and South Asian immigrant parents' experiences of care in paediatric oncology. Child: Care, Health and Development, 2013, 39, 185-193.	1.7	26
44	Single-Parent Caregivers of Children with Cancer. Journal of Pediatric Oncology Nursing, 2013, 30, 45-55.	1.5	26
45	The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes. Haematologica, 2015, 100, 633-642.	3.5	26
46	Molecular analysis and genotypeâ€phenotype correlation of Diamondâ€Blackfan anemia. Clinical Genetics, 2018, 93, 320-328.	2.0	26
47	Quality of life of pediatric oncology patients: Do patient-reported outcome instruments measure what matters to patients?. Quality of Life Research, 2017, 26, 273-281.	3.1	25
48	The burden of disease in pyruvate kinase deficiency: Patients' perception of the impact on healthâ€related quality of life. European Journal of Haematology, 2018, 101, 758-765.	2.2	25
49	Factors affecting the delivery of familyâ€centered care in pediatric oncology. Pediatric Blood and Cancer, 2009, 53, 1079-1085.	1.5	24
50	Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy. Cancer Genetics and Cytogenetics, 2008, 182, 122-125.	1.0	22
51	Thalassaemia in children: from quality of care to quality of life. Archives of Disease in Childhood, 2015, 100, 1051-1057.	1.9	22
52	Nurses provide valuable proxy assessment of the healthâ€related quality of life of children with Hodgkin disease. Cancer, 2010, 116, 1602-1607.	4.1	20
53	Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada. BMC Hematology, 2016, 16, 13.	2.6	20
54	Generation and optimization of the selfâ€administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease. Pediatric Blood and Cancer, 2017, 64, e26588.	1.5	20

#	Article	IF	CITATIONS
55	Impact of caring for a child with cancer on single parents compared with parents from twoâ€parent families. Pediatric Blood and Cancer, 2012, 58, 74-79.	1.5	19
56	Patterns and influences in healthâ€related quality of life in children with immune thrombocytopenia: A study from the Dallas ITP Cohort. Pediatric Blood and Cancer, 2017, 64, e26405.	1.5	19
57	Disease progression in recently diagnosed patients with inherited marrow failure syndromes: A Canadian inherited marrow failure registry (CIMFR) report. Pediatric Blood and Cancer, 2006, 47, 918-925.	1.5	18
58	Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP). Pediatric Blood and Cancer, 2015, 62, 2223-2225.	1.5	18
59	Fatigue in children and adolescents with immune thrombocytopenia. British Journal of Haematology, 2020, 191, 98-106.	2.5	18
60	Quality of life in immune thrombocytopenia following treatment. Archives of Disease in Childhood, 2013, 98, 895-897.	1.9	17
61	Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood, 2018, 132, 448-452.	1.4	16
62	Hemophilia prophylaxis adherence and bleeding using a tailored, frequencyâ€escalated approach: The Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 318-325.	2.3	16
63	IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP. Blood Advances, 2020, 4, 1492-1500.	5.2	16
64	A case of moyamoya syndrome and hemoglobin E/betaâ€ŧhalassemia. Pediatric Blood and Cancer, 2009, 52, 422-424.	1.5	15
65	Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer. European Journal of Cancer, 2016, 64, 101-106.	2.8	15
66	Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study. Blood, 2016, 128, 3633-3633.	1.4	15
67	The diagnosis and treatment of von Willebrand disease in children. Paediatrics and Child Health, 2002, 7, 245-249.	0.6	14
68	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. Platelets, 2016, 27, 472-478.	2.3	14
69	Experience with central venous access devices (<scp>CVAD</scp> s) in the Canadian hemophilia primary prophylaxis study (<scp>CHPS</scp>). Haemophilia, 2015, 21, 469-476.	2.1	13
70	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Advances, 2022, 6, 1844-1853.	5.2	12
71	Parental optimism in poor prognosis pediatric cancers. Psycho-Oncology, 2009, 18, 783-788.	2.3	11
72	Caregiving Demands in Parents of Children With Cancer: Psychometric Validation of the Care of My Child With Cancer Questionnaire. Journal of Pediatric Nursing, 2010, 25, 258-263.	1.5	11

#	Article	IF	CITATIONS
73	Evaluation of health related quality of life in children with immune thrombocytopenia with the PedsQLâ,,¢ 4.0 Generic Core Scales: a study on behalf of the pays de Loire pediatric hematology network. Health and Quality of Life Outcomes, 2013, 11, 193.	2.4	11
74	Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients. Annals of Hematology, 2017, 96, 1937-1944.	1.8	11
75	The social impact of early psychological maturity in adolescents with cancer. Psycho-Oncology, 2019, 28, 586-592.	2.3	11
76	A Prospective Study of the Association Between Clinically Significant Bleeding in PICU Patients and Thrombocytopenia or Prolonged Coagulation Times*. Pediatric Critical Care Medicine, 2017, 18, e455-e462.	0.5	11
77	Understanding the Importance of Using Patient-Reported Outcome Measures in Patients With Immune Thrombocytopenia. Seminars in Hematology, 2013, 50, S39-S42.	3.4	10
78	The clinical impact of copy number variants in inherited bone marrow failure syndromes. Npj Genomic Medicine, 2017, 2, .	3.8	10
79	High-Risk Neuroblastoma in Ontario: A Report of Experience From 1989 to 1995. Journal of Pediatric Hematology/Oncology, 2003, 25, 8-13.	0.6	9
80	Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Diseaseâ€specific assessments. European Journal of Haematology, 2020, 104, 427-434.	2.2	9
81	Factor product utilization and health outcomes in patients with haemophilia A and B on extended halfâ€ife concentrates: A Canadian observational study of realâ€world outcomes. Haemophilia, 2021, 27, 751-759.	2.1	9
82	Introducing the Tran Qol: A New Disease-Specific Quality of Life Measure for Children and Adults with Thalassemia Major. Journal of Blood Disorders & Transfusion, 2013, 04, .	0.1	9
83	Understanding the healthcare experiences of teenaged cancer patients and survivors. Child: Care, Health and Development, 2014, 40, 723-730.	1.7	8
84	Severe Neutropenia and Anemia in a Child With Epilepsy and Copper Deficiency on a Ketogenic Diet. Pediatric Neurology, 2017, 76, 93-94.	2.1	8
85	Androgen therapy in inherited bone marrow failure syndromes: analysis from the Canadian Inherited Marrow Failure Registry. British Journal of Haematology, 2020, 189, 976-981.	2.5	8
86	Health-related quality of life outcomes for patients with immune thrombocytopenic purpura. Annals of Hematology, 2010, 89, 51-54.	1.8	7
87	Characterization of physical literacy in children with chronic medical conditions compared with healthy controls: a cross-sectional study. Applied Physiology, Nutrition and Metabolism, 2021, 46, 1073-1082.	1.9	7
88	Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 249-249.	1.4	7
89	An evidence-based threshold for thrombocytopenia associated with clinically significant bleeding in pediatric intensive care unit patients*. Pediatric Critical Care Medicine, 2012, 13, e316-e322.	0.5	6
90	Cellular and molecular architecture of hematopoietic stem cells and progenitors in genetic models of bone marrow failure. JCI Insight, 2020, 5, .	5.0	6

#	Article	IF	Citations
91	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	1.4	6
92	Central venous catheter thrombosis as a cause of SVC obstruction and cardiac tamponade in a patient with Diamond-Blackfan anemia and iron overload. Pediatric Blood and Cancer, 2006, 46, 112-114.	1.5	5
93	Validation of the school age selfâ€administered pediatric bleeding questionnaire (Selfâ€PBQ) in children aged 8–12Âyears. Pediatric Blood and Cancer, 2019, 66, e27709.	1.5	5
94	Syrian Refugees and Their Impact on Health Service Delivery in the Pediatric Hematology/Oncology Clinics Across Canada. Journal of Pediatric Hematology/Oncology, 2020, 42, e107-e109.	0.6	5
95	Updating the Canadian Hemophilia Outcomes–Kids' Life Assessment Tool (CHOâ€KLAT) in the era of extended halfâ€ife clotting factor concentrates. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 403-411.	2.3	5
96	Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample. Patient Preference and Adherence, 2021, Volume 15, 1407-1417.	1.8	5
97	The impact of extended halfâ€ife factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12601.	2.3	5
98	Patient-reported Outcome Measures in Pediatric Non-Malignant Hematology: A Systematic Review. Journal of Pediatric Hematology/Oncology, 2021, 43, 121-134.	0.6	5
99	Patient-Reported Outcomes Measurement in Radiation Oncology: Interpretation of Individual Scores and Change over Time in Clinical Practice. Current Oncology, 2022, 29, 3093-3103.	2.2	5
100	Quality of life is an important indication for secondâ€ine treatment in children with immune thrombocytopenia. Pediatric Blood and Cancer, 2021, 68, e29023.	1.5	4
101	Magnetic resonance imaging in boys with severe hemophilia A: Serial and endâ€ofâ€study findings from the Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12565.	2.3	4
102	Fatal Neurotoxicity in a Patient With Down Syndrome Treated With Chemotherapy, Irradiation, Stem Cell Transplant, and Clofarabine. Journal of Pediatric Hematology/Oncology, 2010, 32, e111-e113.	0.6	3
103	A survey of the management of newborns with severe hemophilia in Canada. Paediatrics and Child Health, 2013, 18, 189-193.	0.6	3
104	Is the <scp>G</scp> ive <scp>Y</scp> outh a <scp>V</scp> oice questionnaire an appropriate measure of teenâ€centred care in paediatric oncology: a <scp>R</scp> asch measurement theory analysis. Health Expectations, 2015, 18, 1686-1697.	2.6	3
105	Reanalysing genomic data by normalized coverage values uncovers CNVs in bone marrow failure gene panels. Npj Genomic Medicine, 2019, 4, 30.	3.8	3
106	Health-Related Quality of Life. Pediatric Oncology, 2017, , 735-747.	0.5	3
107	Quantitative Assessment of Drug Treatment Side Effects in Children with Idiopathic Thrombocytopenic Purpura (ITP) Blood, 2004, 104, 3030-3030.	1.4	3
108	Vitamin D and Zinc Deficiency Associated with Increased Pain Episodes in Children with Sickle Cell Disease. Blood, 2012, 120, 3237-3237.	1.4	3

#	Article	IF	Citations
109	Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013. Blood, 2018, 132, 4698-4698.	1.4	3
110	SARSâ€CoVâ€2 vaccination in pediatric patients with immune thrombocytopenia. Pediatric Blood and Cancer, 2022, 69, e29760.	1.5	3
111	Using Decision Analysis Techniques to Deal With ???Unanswerable??? Questions in Idiopathic Thrombocytopenic Purpura. Journal of Pediatric Hematology/Oncology, 2003, 25, S62-S63.	0.6	2
112	A <scp>C</scp> anadian survey of selfâ€infusion practices in persons with haemophilia A. Haemophilia, 2012, 18, e403-5.	2.1	2
113	Pediatric Oncology Clinic Care Model: Achieving Better Continuity of Care for Patients in a Medium-sized Program. Journal of Pediatric Hematology/Oncology, 2017, 39, 476-480.	0.6	2
114	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open, 2021, 11, e044885.	1.9	2
115	Neuroblastoma in Down syndrome. , 1999, 33, 125-125.		1
116	Acute immune thrombocytopenic purpura: What do we do when things go well?. Paediatrics and Child Health, 2002, 7, 384-385.	0.6	1
117	Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine. Journal of Pediatric Hematology/Oncology, 2020, 42, 170-174.	0.6	1
118	Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (Hâ€FIT). Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12519.	2.3	1
119	Patterns of joint damage in severe haemophilia A treated with prophylaxis. Haemophilia, 2021, 27, 666-673.	2.1	1
120	Health services use by children identified as heterozygous hemoglobinopathy mutation carriers via newborn screening. BMC Pediatrics, 2021, 21, 296.	1.7	1
121	Successful treatment of pediatric primary hepatic Burkitt lymphoma using rituximab: A case report. Pediatric Blood and Cancer, 2021, 68, e29259.	1.5	1
122	Utility Of The Immature Platelet Fraction In Predicting Recovery With Or Without Treatment In Pediatric Immune Thrombocytopenia. Blood, 2013, 122, 3546-3546.	1.4	1
123	Characterization Of The Immature Platelet Fraction (IPF) Parameters In Children With Immune Thrombocytopenia. Blood, 2013, 122, 3547-3547.	1.4	1
124	Molecular Analysis of Diamond Blackfan Anemia and Genotype-Phenotype Correlation: Experience from the Canadian Inherited Marrow Failure Registry. Blood, 2015, 126, 3621-3621.	1.4	1
125	Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada. Blood, 2018, 132, 4813-4813.	1.4	1
126	Poor outcome after hematopoietic stem cell transplantation of patients with unclassified inherited bone marrow failure syndromes. European Journal of Haematology, 2022, 108, 278-287.	2.2	1

#	Article	IF	CITATIONS
127	Iliopsoas hematoma following a bone marrow aspirate. Pediatric Blood and Cancer, 2008, 51, 146-146.	1.5	O
128	Case 1: A newborn with pancytopenia. Paediatrics and Child Health, 2016, 21, 9-11.	0.6	0
129	Reply to: Vitamin insufficiencies/deficiencies in relation to sickle cell disease severity and associated morbidity. Pediatric Blood and Cancer, 2016, 63, 2250-2251.	1.5	0
130	Azacitidine in Children with Advanced Myelodysplastic Syndrome as a Bridging Treatment Prior to Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S263-S264.	2.0	0
131	Reply to comment on: Generation and optimization of the selfâ€administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease. Pediatric Blood and Cancer, 2017, 64, e26763.	1.5	0
132	Affairs of the heart, does congenital heart disease make you happier?. Archives of Disease in Childhood, 2019, 104, 105-105.	1.9	0
133	Successful use of recombinant activated factor VII administered via automated bolus pump following emergency laparoscopic appendectomy in a patient with mild congenital FVII deficiency: Case report. Pediatric Blood and Cancer, 2021, 68, e28974.	1.5	0
134	Immune tolerance induction using Fcâ€fusionâ€protein recombinant factor IX in severe haemophilia B. Haemophilia, 2021, 27, e776-e779.	2.1	0
135	Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia Blood, 2010, 116, 3681-3681.	1.4	0
136	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood, 2010, 116, 2509-2509.	1.4	0
137	Outcome and Clinical Characteristics of Clonal and Malignant Myeloid Transformation in Inherited Bone Marrow Failure Syndromes. Blood, 2012, 120, 1266-1266.	1.4	0
138	Pediatric Oncology Clinic Care Model: How to Care for Patients to Achieve Better Continuity of Care in a Medium Sized Program. Blood, 2014, 124, 6000-6000.	1.4	0
139	Preliminary International Validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Blood, 2014, 124, 1328-1328.	1.4	0
140	Risk Factors for Poor Survival after Hematopoietic Stem Cell Transplantation in Inherited Bone Marrow Failure Syndromes. Blood, 2014, 124, 2592-2592.	1.4	0
141	Application of Novel Next Generation Sequencing Gene Panel Assay to Genetic and Clinical Diagnosis of Inherited Bone Marrow Failure Syndromes. Blood, 2014, 124, 257-257.	1.4	0
142	Second Line ITP Therapy in the UK: Results from the UK Paediatric ITP Registry. Blood, 2015, 126, 3478-3478.	1.4	0
143	Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes. Blood, 2015, 126, 2416-2416.	1.4	0
144	a Randomized, Double-Blinded, Placebo Controlled Study of IVIG Vs. IVIG with High Dose Methylprednisolone in Rapidly Augmenting Platelet Counts in Childhood ITP. Blood, 2016, 128, 868-868.	1.4	0

#	Article	lF	CITATIONS
145	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. Blood, 2016, 128, 1008-1008.	1.4	0
146	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 4752-4752.	1.4	0
147	Predictors of Hydroxyurea Use in Children with Sickle Cell Disease. Blood, 2018, 132, 4934-4934.	1.4	0
148	Development of Patient-Reported Outcome Measures (Symptoms and Impacts) in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 3447-3447.	1.4	0
149	Evaluating the Impact of Thrombopoietin Receptor Agonists Medications on Patient Outcomes and Quality of Life in Pediatric Immune Thrombocytopenia. Blood, 2021, 138, 4072-4072.	1.4	0
150	Pharmacist Integration into the Hemophilia Treatment Centre: A Canadian Pilot Project to Optimize Treatment and Improve Cost-Savings Using Pharmacokinetic Assessments of Hemophilia Patients. Blood, 2021, 138, 832-832.	1.4	0
151	Genotypic and Phenotypic Spectrum of Dyskeratosis Congenita: Results from the Canadian Inherited Marrow Failure Registry. Blood, 2020, 136, 8-9.	1.4	0
152	Novel cysteine substitution p.(Cys $1084Tyr$) causes variable expressivity of qualitative and quantitative VWF defects. Blood Advances, 2022 , , .	5.2	0
153	Clinical Measures., 0,, 89-98.		0
154	Integration of Patient-reported Outcome Measures in Pediatric Hematology: A Qualitative Methods Study. Journal of Pediatric Hematology/Oncology, 2022, Publish Ahead of Print, .	0.6	0